COVID-19 Publications - Week 17 2021 1448 Publications
Total Page:16
File Type:pdf, Size:1020Kb
Update April 26 - May 02, 2021, Dr. Peter J. Lansberg MD, PhD Weekly COVID-19 Literature Update will keep you up-to-date with all recent PubMed publications categorized by relevant topics COVID-19 publications - Week 17 2021 1448 Publications PubMed based Covid-19 weekly literature update For those interested in receiving weekly updates click here For questions and requests for topics to add send an e-mail [email protected] Reliable on-line resources for Covid 19 WHO Cochrane Daily dashbord BMJ Country Guidance The Lancet Travel restriction New England Journal of Medicine Covid Counter JAMA Covid forcasts Cell CDC Science AHA Oxford Universtiy Press ESC Cambridge Univeristy Press EMEA Springer Nature Evidence EPPI Elsevier Wikipedia Wiley Cardionerds - COVID-19 PLOS Genomic epidemiology LitCovid NIH-NLM Oxygenation Ventilation toolkit SSRN (Pre-prints) German (ICU) bed capacity COVID reference (Steinhauser Verlag) COVID-19 Projections tracker Retracted papers AAN - Neurology resources COVID-19 risk tools - Apps COVID-19 resources (Harvard) Web app for SARS-CoV2 mutations COVID-19 resources (McMasters) COVID-19 resources (NHLBI) COVID-19 resources (MEDSCAPE) COVID-19 Diabetes (JDRF) COVID-19 TELEMEDICINE (BMJ) Global Causes of death (Johns Hopkins) COVID-19 calculators (Medscap) Guidelines NICE Guidelines Covid-19 Korean CDC Covid-19 guidelines Flattening the curve - Korea IDSA COVID-19 Guidelines Airway Management Clinical Practice Guidelines (SIAARTI/EAMS, 2020) ESICM Ventilation Guidelines Performing Procedures on Patients With Known or Suspected COVID-19 (ASA, 2020) OSHA Guidance on Preparing the Workplace for COVID-19 (2020) Policy for Sterilizers, Disinfectant Devices, and Air Purifiers (FDA, 2020) Breast Cancer Patient Triage Guidelines (CPBCC, 2020) clinical guidance for adult Belgian patients with suspected or confirmed COVID-19 National Covid-19 Testing Action Plan (Rockefeller Foundation) ASE issues Echo-cardiography guidance Trials & Registries CAPACITY European registry COVID 19 patients WHO launches global megatrial FDA launches Convalescent plasma trial Lets Beat Covid-19 Survey to help plan hospital services COVID IBD registry Google mobility reports per country COVID 19 World's largest trial of potential coronavirus treatments rolled out across the UK Pregnancy Registry (US) ICNARC report on COVID-19 in critical care - NHS April 24 COVID-19 Human Genetics - Biobanks COVID19 settings of transmission database COVID-19 prevention network Covid-Plex trial - (plasma exchange & convalescent plasma trial) The Covid-Plex trial is an investigator initiated, multicenter, parallel-group, open-label randomized clinical trial aiming to randomize patients with severe COVID-19 to standard care or standard care plus plasmapheresis and convalescent plasma. If you are interested to participate Please contact Wladimir Szpirt, Nicholas Carlson Anders, or Perner Bo Feldt-Rasmussen. Depts. Of Intensive Care Therapy and Nephrology, Copenhagen University Hospital Rigshospitalet, Denmark Covid-Plex trial Mainstream Media New York Times - Corona update India’s vaccinations decline as its virus outbreak reaches new highs. Europe signals it may not support Biden’s call to waive Covid vaccine patents. Millions of Johnson & Johnson doses sit unused across three continents. Australia confirms it will allow its citizens to return home from India starting May 15, Want a coronavirus vaccine? U.S. pharmacies say walk right in. Pregnant women in Britain will be offered Covid-19 vaccines. Pfizer-BioNTech Vaccine is Highly Effective Against Variants, Studies Find Millions Are Skipping Their Second Doses of Covid Vaccines How Hard Could It Be to Vaccinate the Whole World? Washington Post - Corona update Drug companies dig in for global patent fight amid flow of billions in vaccine revenue The pandemic has led to innovation. It’s a reason for optimism. 149.5 million vaccinated Germany lets the vaccinated have a bit more fun. Teens shut out from the jabs are not happy. Europe's vaccine campaign is accelerating. It expects to match the U.S. by July. We could see a winter comeback of covid-19 if we don’t get more Americans vaccinated now Guardian - Corona update Covid-19 unlikely to be ever eradicated, warns Prof Chris Whitty New concerns as Indian Covid variant clusters found across England Tui to offer £20 Covid tests for travellers to green list countries EU wants to mass produce three ‘course-changing’ Covid drugs from October IOC and Pfizer strike vaccine deal for Tokyo Olympics competitors Key Articles 1. COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. Pharmaceuticals (Basel) 2021; 14Yan ZP, Yang M, Lai CL. http://www.ncbi.nlm.nih.gov/pubmed/?term=33923054 In this phase of the COVID, pandemic vaccination efforts have become the focus of attention. To date, 86 vaccines are under development. This review shares the most relevant information of 12 vaccines currently deployed or very close to being released for clinical use. Efficacy and safety data of these vaccines in various populations are presented in a concise and systematic overview to provide health care providers with relevant information. 2. Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database. Vaccines (Basel) 2021; 9Tobaiqy M, Elkout H, MacLure K. http://www.ncbi.nlm.nih.gov/pubmed/? term=33923530 From March 11th, several European countries suspended the use of the Astra Zeneca Oxford vaccine. The European Medical Agency (EMA) and World Health Organization came out with reassuring reports, and most, but not all, countries re-started the use of the Astra Zeneca Oxford vaccine. This review shares data collected in the Eudora Vigilance registry from February 17th – March 12th. Of the 17 million individuals that received the vaccine, 54 571 reported adverse events. Thrombotic complications occurred in 28 individuals, of which three died from pulmonary embolisms and one from thrombosis. The observed fatal complications were classified as extremely rare events, and the EMA concluded that the benefits far outweighed the risks. 3. Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia. Stroke 2021; American Heart Association/American Stroke Association Stroke Council L. http://www.ncbi.nlm.nih.gov/pubmed/?term=33914590 Cerebral venous sinus thrombosis (CVST) is an extremely thrombotic rare complication that was reported in six cases after use of the Jansen – Johnson & Johnsen (JJJ) vaccine. Thrombotic complications were also reported after the use of the Astra Zeneca Oxford vaccine. Both vaccines share the use of adenoviral vectors. The mRNA based Pfizer and Moderna vaccines did not report any cases of thrombocytopenia associated CVST in 187 million vaccinated individuals. After initial suspension of the JJJ vaccine, the FDA has authorized the continuation of this vaccine, but advised clinicians to be aware of this extremely rare complication and this review provides clinicians with helpful information on CVST diagnosis and management 4. E-Triage Systems for COVID-19 Outbreak: Review and Recommendations. Sensors (Basel) 2021; 21Alhaidari F, Almuhaideb A, Alsunaidi S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33920744 5. Statin Use Is Associated with a Decreased Risk of Mortality among Patients with COVID-19. J Clin Med 2021; 10Wu CC, Lee AJ, Su CH et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33916281 6. Thrombocytopenia and Intracranial Venous Sinus Thrombosis after "COVID-19 Vaccine AstraZeneca" Exposure. J Clin Med 2021; 10Wolf ME, Luz B, Niehaus L et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33918932 7. Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19): current updates. Antib Ther 2020; 3:115- 125Verma HK, Farran B, Bhaskar L. http://www.ncbi.nlm.nih.gov/pubmed/? term=33912791 8. Development and validation of the long covid symptom and impact tools, a set of patient-reported instruments constructed from patients' lived experience. Clin Infect Dis 2021; Tran VT, Riveros C, Clepier B et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33912905 9. Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management. Int J Environ Res Public Health 2021; 18Sisó- Almirall A, Brito-Zerón P, Conangla Ferrín L et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33923972 10. Cancer as a prospective sequela of long COVID-19. Bioessays 2021:e2000331Saini G, Aneja R. http://www.ncbi.nlm.nih.gov/pubmed/? term=33914346 11. Neurological update: COVID-19. J. Neurol. 2021:1-9Ren AL, Digby RJ, Needham EJ. http://www.ncbi.nlm.nih.gov/pubmed/?term=33929617 12. COVID-19: Direct and Indirect Mechanisms of Statins. Int J Mol Sci 2021; 22Pawlos A, Niedzielski M, Gorzelak-Pabiś P et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33920709 13. mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci 2021; 17:1446-1460Park JW, Lagniton PNP, Liu Y, Xu RH. http://www.ncbi.nlm.nih.gov/pubmed/?term=33907508 14. Safety of COVID-19 vaccines administered in the EU: Should we be concerned? Toxicol Rep 2021; 8:871-879Hernández AF, Calina D, Poulas K et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33898273 15. COVID-19 and Pregnancy: Risk, Symptoms, Diagnosis, and Treatment. SN Compr Clin Med 2021:1-7Hapshy V, Aziz D, Kahar P et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=3389892 Basic Science (93 articles) 1. Analysis of the Genomic Distance Between Bat Coronavirus RaTG13 and SARS-CoV-2 Reveals Multiple Origins of COVID-19. Acta Math Sci 2021; 41:1017-1022Pei S, Yau SS. http://www.ncbi.nlm.nih.gov/pubmed/?term=33897081 2. Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing LianhuaQingwen capsule. Acta Pharmacol. Sin. 2021:1-18Lan XF, Olaleye OE, Lu JL et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33931765 3. Quantitative Evaluation of Aerosol Generation from Non-contact Tonometry and its Correlation with Tear Film Characteristics. Adv Ther 2021:1-11Hao W, Wu J, Zhao X et al.